• Company
• First oHCM drug Camzyos applies for reimb in Korea
• by Eo, Yun-Ho Jan 22, 2024 05:49am

• Policy
• Forxiga withdraws from the Korean mkt despite reimbursement
• by Lee, Tak-Sun Jan 22, 2024 05:48am

• Policy
• P3T for chin fat reduction injection ‘AYP-101’ approved
• by Lee, Hye-Kyung Jan 19, 2024 05:45am

• Policy
• Emerging candidate for Dir. of the Pharmaceutical Benefits
• by Lee, Jeong-Hwan Jan 19, 2024 05:45am

• Policy
• Celltrion rebrands and sells self-manufactured drugs
• by Lee, Hye-Kyung Jan 19, 2024 05:44am

• Company
• Hemlibra reduces risk of exercise-associated bleeding
• by Lee, Seok-Jun Jan 19, 2024 05:44am

• Opinion
• [Reporter’s View] Forxiga withdrawal raises concern
• by Son, Hyung-Min Jan 19, 2024 05:44am

• Company
• Keytruda's reimb for 6 indications will be reviewed
• by Eo, Yun-Ho Jan 19, 2024 05:44am

• Company
• AstraZeneca begins ERP and business unit restructuring
• by Son, Hyung-Min Jan 18, 2024 04:51pm

• Company
• Keytruda approved as 1st-line treatment for gastric cancer
• by Son, Hyung-Min Jan 18, 2024 04:46pm